Please Wait
Applying Filters...
menu
    • menu
    IOL Chemicals is an innovation-driven bulk drug, Intermediate and Specialty Chemicals company.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Privosegtor

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Oculis To Participate In Upcoming November Investor Conferences
    Oculis To Participate In Upcoming November Investor Conferences

    05 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/05/3181132/0/en/Oculis-to-Participate-in-Upcoming-November-Investor-Conferences.html

    GLOBENEWSWIRE
    05 Nov 2025
    Share Share
    Oculis Announces Oversubscribed $110 Million Financing
    Oculis Announces Oversubscribed $110 Million Financing

    30 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/30/3177102/0/en/Oculis-Announces-Oversubscribed-110-Million-Financing-to-Accelerate-Privosegtor-Development.html

    GLOBENEWSWIRE
    30 Oct 2025
    Share Share
    Oculis Showcases Late-Stage Pipeline At Eyecelerator & AAO 2025
    Oculis Showcases Late-Stage Pipeline At Eyecelerator & AAO 2025

    14 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/14/3165923/0/en/Oculis-to-Spotlight-Transformative-Late-Stage-Pipeline-at-Eyecelerator-and-AAO-2025.html

    GLOBENEWSWIRE
    14 Oct 2025
    Share Share
    Oculis Advances Privosegtor To Registrational In Optic Neuritis
    Oculis Advances Privosegtor To Registrational In Optic Neuritis

    06 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/06/3161455/0/en/Oculis-Accelerates-Privosegtor-into-Registrational-Trials-in-Acute-Optic-Neuritis-Pioneering-the-Path-for-a-Potential-First-in-class-Neuroprotective-Therapy.html

    GLOBENEWSWIRE
    06 Oct 2025
    Share Share
    Oculis Presents Phase 2 Acuity Trial Results With Privosegtor
    Oculis Presents Phase 2 Acuity Trial Results With Privosegtor

    22 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/22/3153669/0/en/Oculis-Announces-Presentation-of-Phase-2-ACUITY-trial-results-with-Privosegtor-in-Acute-Optic-Neuritis-at-ECTRIMS.html

    GLOBENEWSWIRE
    22 Sep 2025
    Share Share
    Oculis to Host In-Person and Virtual R&D Day on Business Updates
    Oculis to Host In-Person and Virtual R&D Day on Business Updates

    01 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/01/3053047/0/en/Oculis-to-Host-In-Person-and-Virtual-R-D-Day-on-Key-Business-Updates-and-the-Development-Plans-for-Privosegtor-OCS-05-in-Acute-Optic-Neuritis-and-Beyond.html

    GLOBENEWSWIRE
    01 Apr 2025
    Share Share